ZAP-70 Promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Calpe, Eva ^a   Purroy, Noelia ^a   Carpio, Cecilia ^a   Abrisqueta, Pau ^a   Carabia, Júlia ^a   Palacio, Carles ^a   Castellví, Josep ^a   Crespo, Marta ^a   Bosch, Francesc ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN KINASE B; PROTEIN KINASE ZAP 70; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; IMMUNOSTIMULATION; IN VITRO STUDY; INTRACELLULAR SIGNALING; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAJI CELL; STROMA CELL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANIMALS; B-LYMPHOCYTES; BONE MARROW; CELL MOVEMENT; CHEMOKINE CXCL12; HUMANS; JURKAT CELLS; LEUKEMIA, B-CELL; MICE; MICE, SCID; NEOPLASM PROTEINS; RECEPTORS, CXCR4; STROMAL CELLS; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84891774347     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081221     Document Type: Article

References (46)

1. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, et al. (2005) In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. Journal of Clinical Investigation 115: 755-764.
2. Giné E, Martinez A, Villamor N, Lopez-Guillermo A, Camos M, et al. (2010) Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 95: 1526-1533.
3. Ticchioni M, Essafi M, Jeandel PY, Davi F, Cassuto JP, et al. (2007) Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Oncogene 26: 7081-7091.
4. Ghamlouch H, Ouled-Haddou H, Damaj G, Royer B, Gubler B, et al. (2013) A Combination of Cytokines Rescues Highly Purified Leukemic CLL B-Cells from Spontaneous Apoptosis In Vitro. PLoS ONE 8: e60370.
5. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, et al. (2003) Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 101: 1087-1093.
6. Caligaris-Cappio F (2003) Role of the microenvironment in chronic lymphocytic leukaemia. British journal of haematology 123: 380-388.
7. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F (2009) The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114: 3367-3375.
8. Ferretti E, Bertolotto M, Deaglio S, Tripodo C, Ribatti D, et al. (2011) A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. Leukemia 25: 1268-1277.
9. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, et al. (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. New England Journal of Medicine 348: 1764-1775.
10. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, et al. (2004) ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. New England Journal of Medicine 351: 893-901.
11. Dürig J, Nückel H, Cremer M, Führer A, Halfmeyer K, et al. (2003) ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 17: 2426-2434.
12. Richardson SJ, Matthews C, Catherwood MA, Alexander HD, Carey BS, et al. (2006) ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107: 3584.
13. Deaglio S, Vaisitti T, Aydin S, Bergui L, D'Arena G, et al. (2007) CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 110: 4012-4021.
14. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, et al. (2009) B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 114: 1029-1037.
15. Messmer D, Fecteau JF, O'Hayre M, Bharati IS, Handel TM, et al. (2011) Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood 117: 882-889.
16. Calpe E, Codony C, Baptista MJ, Abrisqueta P, Carpio C, et al. (2011) ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation. Blood 118: 4401-4410.
17. Stamatopoulos B, Haibe-Kains B, Equeter C, Meuleman N, Sorée A, et al. (2009) Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA. Haematologica 94: 790-799.
18. Zum Büschenfelde CM, Wagner M, Lutzny G, Oelsner M, Feuerstacke Y, et al. (2009) Recruitment of PKC-βII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. Leukemia 24: 141-152.
19. Guinamard R, Signoret N, Ishiai M, Marsh M, Kurosaki T, et al. (1999) B cell antigen receptor engagement inhibits stromal cell-derived factor (SDF)-1α chemotaxis and promotes protein kinase C (PKC)-induced internalization of CXCR4. The Journal of experimental medicine 189: 1461.
20. Casamayor-Pallejà M, Mondière P, Verschelde C, Bella C, Defrance T (2002) BCR ligation reprograms B cells for migration to the T zone and B-cell follicle sequentially. Blood 99: 1913-1921.
21. Guarini A, Chiaretti S, Tavolaro S, Maggio R, Peragine N, et al. (2008) BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells. Blood 112: 782-792.
22. Vlad A, Deglesne PA, Letestu R, Saint-Georges S, Chevallier N, et al. (2009) Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer research 69: 6387.
23. Itoh K, Tezuka H, Sakoda H, Konno M, Nagata K, et al. (1989) Reproducible establishment of hemopoietic supportive stromal cell lines from murine bone marrow. Exp Hematol 17: 145-53
24. Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, et al. (2007) Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110: 2569-2577.
25. Chang CH, Sapra P, Vanama SS, Hansen HJ, Horak ID, et al. (2005) Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/ anti-CD74 humanized IgG4 antibody immunotoxin. Blood 106: 4308-4314.
26. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA (1996) A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). The Journal of experimental medicine 184: 1101-1109.
27. Vaisitti T, Aydin S, Rossi D, Cottino F, Bergui L, et al. (2010) CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia 24: 958-969.
28. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, et al. (2005) Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106: 1824-1830.
29. Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, et al. (2005) Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α. Blood 106: 1012-1020.
30. Bertolini F, Dell'Agnola C, Mancuso P, Rabascio C, Burlini A, et al. (2002) CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Research 62: 3106-3112.
31. Bertilaccio MTS, Scielzo C, Simonetti G, Hacken ET, Apollonio B, et al. (2012) Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. Leukemia 27: 534-540.
32. Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, et al. (2007) ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 109: 2032-2039.
33. Chan AC, Iwashima M, Turck CW, Weiss A (1992) ZAP-70: a 70 kd proteintyrosine kinase that associates with the TCR zeta chain. Cell 71: 649-662.
34. Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, et al. (2005) ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 105: 2036-2041.
35. Chen L, Huynh L, Apgar J, Tang L, Rassenti L, et al. (2008) ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 111: 2685-2692.
36. Ticchioni M, Charvet C, Noraz N, Lamy L, Steinberg M, et al. (2002) Signaling through ZAP-70 is required for CXCL12-mediated T-cell transendothelial migration. Blood 99: 3111-3118.
37. Kremer KN, Humphreys TD, Kumar A, Qian NX, Hedin KE (2003) Distinct role of ZAP-70 and Src homology 2 domain-containing leukocyte protein of 76 kDa in the prolonged activation of extracellular signal-regulated protein kinase by the stromal cell-derived factor-1α/CXCL12 chemokine. The Journal of Immunology 171: 360.
38. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, et al. (2009) Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 113: 5549-5557.
39. Buchner M, Baer C, Prinz G, Dierks C, Burger M, et al. (2010) Spleen tyrosine kinase inhibition prevents chemokine-and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 115: 4497-4506.
40. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, et al. (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119: 1182-1189.
41. De Rooij MFM, Kuil A, Geest CR, Eldering E, Chang BY, et al. (2012) The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119: 2590-4.
42. Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, et al. (2012) Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 26: 1576-1583.
43. Byrd JC, Furman RR, Coutre S, Flinn IW, Burger JA, et al. (2012) The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naive (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High- Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study. ASH Annual Meeting Abstracts 120: 189.
44. Furman RR, Byrd JC, Brown JR, Coutre SE, Benson DM, et al. (2010) CAL- 101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110d, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts 116: 55.
45. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, et al. (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115: 2578-2585.
46. Muntañola A, Bosch F, Arguis P, Arellano-Rodrigo E, Ayuso C, et al. (2007) Abdominal Computed Tomography Predicts Progression in Patients With Rai Stage 0 Chronic Lymphocytic Leukemia. JCO 25: 1576-1580.